Two groups of patients, each consisting of 20 patients suffering from spinal
osteoarthrosis,
coxarthrosis or gonarthrosis participated in a double-blind comparative trial. They received either
Lonazolac-Ca (200 mg three times daily) or
Naproxen (250 mg twice daily plus 1 placebo
capsule in between doses) for three weeks. The therapeutic response was assessed by monitoring
pain intensity at rest and on exercise, joint tenderness and joint movement, muscular tension, morning stiffness and walking ability. In spinal
osteoarthrosis vertebral flexibility was also measured. Nine out of 11 parameters showed significant improvement with
Lonazolac-Ca, whereas only 6 out of 11 improved with
Naproxen. However, no clinically relevant differences were recorded between both medications. Laboratory tests in both treatment groups revealed no changes in haematological or biochemical parameters nor in urinanalysis results.
Drug-related gastro-intestinal side effects were observed in 2 patients of each treatment group. The patients on
Lonazolac-Ca tolerated their medication with the aid of concomitant
antacids whereas
Naproxen had to be discontinued. One case of
dermatitis, which was probably not
drug-related was observed in each group. One patient suffering from
migraine experienced
vertigo and
headache on taking
Lonazolac-Ca; although this was probably not
drug-related medication was discontinued.